Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Umeclidinium

Classification: A

Drug products: ANORO ELLIPTA, Incruse Ellipta, Trelegy Ellipta

ATC code: R03AL03, R03AL08, R03BB07

Substances: umeclidinium, umeclidinium bromide

Summary

Limited data from controlled trials with umeclidinium, does not suggest any notable difference in the effect or pharmacokinetics between men and women.

Additional information

COPD (chronic obstructive pulmonary disease) affects more women than men and women often get a more serious and rapidly progressive disease [1].

Pharmacokinetics and dosing

Population pharmacokinetic analysis (69% male) showed no evidence of a clinically significant sex difference in systemic exposure of umeclidinium [2].

Effects

Population pharmacokinetic analysis (69% male) showed no evidence of a clinically significant sex difference in effect [2].

Adverse effects

No studies with a clinically relevant sex analysis regarding the adverse effects of umeclidinium have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2020-11-13

Date of litterature search: 2020-11-02

References

  1. Nationella riktlinjer för vård vid astma och kroniskt obstruktiv lungsjukdom (KOL). Socialstyrelsen. [updated 2018-01-29, cited 2020-09-14]. länk
  2. Food and Drug Adinistration (FDA). Prescribing information - ANORO ELLIPTA (umeclidinium and vilanterol). Drugs@FDA [www]. [updated 2013-12-01, cited 2020-09-30]. länk
  3. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.] länk

Authors: Ishita Huq, Linnéa Karlsson Lind

Reviewed by: Diana Rydberg, Carl-Olav Stiller

Approved by: Karin Schenck-Gustafsson